29 completed, 8 terminated, 4 unknown, 3 active not recruiting. 16 Phase 4, 13 Phase 2, 10 Phase 3, 4 Phase 1.
Follow Simulect: new trials by email Literature Review of Simulect trials Research Report on Simulect
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 1 vs 7 RATG Infusions in Renal Transplantation RATG, Basiliximab - Kidney Replacement | Active not recruiting | Mario Negri Institute for Pharmacological Research | 75 | 2024-07-30 | 2025-09-04 | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 7 | 2022-07-19 | 2026-07-06 |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma Basiliximab, Carmustine, Cytarabine - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2021-11-02 | 2025-12-04 |
| Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection | Phase 2 | Unknown | Fort Worth Clinical Sciences Working Group | 300 | 2021-10-15 | 2021-08-19 |
| Impact of the Microbiota on the Likelihood of Renal Graft Rejection Belatacept Injection [Nulojix] - Kidney Transplant Rejection | Active not recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 70 | 2021-10-07 | 2026-08-03 | |
| Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Busulfan, Cyclophosphamide, Fludarabine - Thalassemia Major | Phase 4 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2017-04-01 | 2017-05-31 |
| Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients Basiliximab, Thymoglobulin - Kidney Transplant Rejection, Kidney Transplant; Complications | Phase 4 | Completed | Coordinación de Investigación en Salud, Mexico | 100 | 2016-12-01 | 2019-11-15 |
| Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients sirolimus, tacrolimus, mycophenolate - Disorder Related to Renal Transplantation, Cytomegalovirus Infections | Phase 4 | Completed | Associação Médico Espírita de Botucatu | 48 | 2014-01-01 | 2016-02-17 |
| Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Basiliximab, Methylprednisolone, Prednisone - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | Emory University | 31 | 2013-10-01 | 2017-11-06 |
| Simulect Versus ATG in Sensitized Renal Transplant Patient Simulect, ATG Fresenius - Renal Transplant Rejection | Phase 4 | Completed | University Hospital, Toulouse | 60 | 2013-09-01 | 2026-04-08 |
| Pediatric Induction Therapy in Kidney Transplantation Basiliximab Injection, rabbit ATG - Kidney Transplant Rejection, Pediatric Kidney Disease | Completed | Gang Chen | 958 | 2013-03-03 | 2023-10-17 | |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma basiliximab, carmustine, etoposide - Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 25 | 2013-02-13 | 2026-10-15 |
| 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Everolimus, Tacrolimus, Cyclosporin A - Kidney Transplantation, Renal Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 612 | 2012-12-27 | 2017-05-01 |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | University of Chicago | 7 | 2011-12-05 | 2018-03-09 |
| Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease Infliximab and Basiliximab - Graft Versus Host Disease, Steroid Refractory GVHD | Phase 2 | Terminated | Nationwide Children's Hospital | 11 | 2011-12-01 | 2019-04-05 |
| Stem Cell Transplantation for Patients With Multiple Myeloma G-CSF, Plerixafor, Apheresis - Myeloma | Phase 1 | Completed | University of Chicago | 30 | 2011-07-12 | 2025-11-05 |
| A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids Advagraf, Mycophenolate Mofetil, Simulect - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Inc | 1166 | 2011-01-22 | 2024-11-01 |
| Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment ATG-F, Simulect - Glomerulonephritis, IgAN | Phase 4 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 117 | 2011-01-08 | 2021-01-20 |
| Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation Basiliximab, Tacrolimus, Mycophenolic Acid - Liver Transplantation | Phase 4 | Completed | University of California, Los Angeles | 59 | 2011-01-01 | 2022-09-29 |
| Thymoglobulin Induction in Kidney Transplant Recipients antithymocyte globulin, Basiliximab - Kidney Transplantation, Ischemia-Reperfusion Injury | Phase 3 | Unknown | University of Oxford | 40 | 2011-01-01 | 2010-11-11 |
Showing 20 of 45. Sign in to see all of them.
Hodgkin Disease (3) · Kidney Failure, Chronic (3) · Colitis, Ulcerative (2) · Graft vs Host Disease (2) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Renal Insufficiency (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · COVID-19 (1) · Congenital Abnormalities (1) · Cytokine Release Syndrome (1) · Cytomegalovirus Infections (1) · Diabetes Mellitus (1)
Astellas Pharma Inc (6) · Novartis Pharmaceuticals (5) · Cerimon Pharmaceuticals (3) · City of Hope Medical Center (3) · Novartis (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Chicago (2) · University of Oxford (2) · Associação Médico Espírita de Botucatu (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Coordinación de Investigación en Salud, Mexico (1) · Drexel University College of Medicine (1) · Emory University (1) · First Affiliated Hospital of Guangxi Medical University (1) · Fort Worth Clinical Sciences Working Group (1)
United States (19) · Germany (8) · France (7) · United Kingdom (6) · Belgium (5) · Switzerland (5) · Czechia (4) · Italy (4) · Mexico (4) · Poland (4) · Russia (4) · Sweden (4) · Austria (3) · Canada (3) · Hungary (3)
A.M. James Shapiro, MD, PhD (1) · Alex F Herrera (1) · Andreas A Schnitzbauer, MD (1) · Antoine Durrbach, MD-PhD (1) · Carlo Gerardo B Ramirez, M.D. (1) · Christian Hugo, Prof. Dr. (1) · Christina N Fournier, MD (1) · Colin Baigent (1) · Daniel Levitt, MD, PhD (1) · Eileen Smith (1)
PMID 39382091, PMID 16699456, PMID 17093248, PMID 18416737, PMID 19663893, PMID 20840760, PMID 22549092, PMID 22850297, PMID 23230975, PMID 23422495, PMID 23438305, PMID 23641902, PMID 25078310, PMID 26018348, PMID 26888217, PMID 27547871, PMID 27871759, PMID 29149958, PMID 29226570, PMID 29308669, PMID 29344432, PMID 30582281, PMID 31029086, PMID 31536556, PMID 31940591, PMID 32775820, PMID 33277746, PMID 34638132, PMID 37391381, PMID 38993854, PMID 39082471, PMID 39739990
2008 (3), 2009 (2), P30CA033572 (2), 2005 (1), P01CA030206 (1), P50CA107399 (1), R21CA185875 (1)